cancer vaccines

Summary

Summary: Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.

Top Publications

  1. pmc Improved survival with ipilimumab in patients with metastatic melanoma
    F Stephen Hodi
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 363:711-23. 2010
  2. ncbi Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    Philip W Kantoff
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 363:411-22. 2010
  3. pmc Cancer immunotherapy comes of age
    Ira Mellman
    Genentech, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 480:480-9. 2011
  4. ncbi Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
    Jedd D Wolchok
    Ludwig Center for Cancer Immunotherapy and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 15:7412-20. 2009
  5. pmc gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma
    Douglas J Schwartzentruber
    Indiana University Health Goshen Center for Cancer Care, Goshen, IN 46526, USA
    N Engl J Med 364:2119-27. 2011
  6. ncbi Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival
    Yu Sawada
    Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Clin Cancer Res 18:3686-96. 2012
  7. ncbi Cancer/testis (CT) antigens: potential targets for immunotherapy
    Otavia L Caballero
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York City, USA
    Cancer Sci 100:2014-21. 2009
  8. ncbi The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research
    Martin A Cheever
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Clin Cancer Res 15:5323-37. 2009
  9. ncbi PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine
    Martin A Cheever
    Clinical Research Division, Fred Hutchinson Cancer Research Center, and Division of Medical Oncology, University of Washington, Seattle, WA 98109, USA
    Clin Cancer Res 17:3520-6. 2011
  10. pmc Cancer immunotherapy: moving beyond current vaccines
    Steven A Rosenberg
    Surgery Branch of the Center for Cancer Research at the National Cancer Institute, Building 10, Room 2B42, 10 Center Drive, MSC 1502 Bethesda, Maryland 20892 1502, USA
    Nat Med 10:909-15. 2004

Detail Information

Publications341 found, 100 shown here

  1. pmc Improved survival with ipilimumab in patients with metastatic melanoma
    F Stephen Hodi
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 363:711-23. 2010
    ....
  2. ncbi Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    Philip W Kantoff
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 363:411-22. 2010
    ..Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer...
  3. pmc Cancer immunotherapy comes of age
    Ira Mellman
    Genentech, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 480:480-9. 2011
    ....
  4. ncbi Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
    Jedd D Wolchok
    Ludwig Center for Cancer Immunotherapy and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 15:7412-20. 2009
    ..Novel criteria for the evaluation of antitumor responses with immunotherapeutic agents are required...
  5. pmc gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma
    Douglas J Schwartzentruber
    Indiana University Health Goshen Center for Cancer Care, Goshen, IN 46526, USA
    N Engl J Med 364:2119-27. 2011
    ....
  6. ncbi Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival
    Yu Sawada
    Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Clin Cancer Res 18:3686-96. 2012
    ..In this nonrandomized, open-label, phase I clinical trial, we analyzed the safety and efficacy of GPC3 peptide vaccination in patients with advanced HCC...
  7. ncbi Cancer/testis (CT) antigens: potential targets for immunotherapy
    Otavia L Caballero
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York City, USA
    Cancer Sci 100:2014-21. 2009
    ..Cancer vaccine trials based on CT antigens MAGE-A3 and NY-ESO-1 are currently ongoing, and these antigens may also play a role in antigen-specific adoptive T-cell transfer and in the immunomodulation approach of cancer therapy...
  8. ncbi The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research
    Martin A Cheever
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Clin Cancer Res 15:5323-37. 2009
    ..status of the cancer vaccine field, highlight the possibility that additional organized efforts and funding would accelerate the development of therapeutically effective cancer vaccines, and accentuate the need for prioritization.
  9. ncbi PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine
    Martin A Cheever
    Clinical Research Division, Fred Hutchinson Cancer Research Center, and Division of Medical Oncology, University of Washington, Seattle, WA 98109, USA
    Clin Cancer Res 17:3520-6. 2011
    ..The preclinical and clinical development of sipuleucel-T is reviewed, and approaches to enhance efficacy are considered herein...
  10. pmc Cancer immunotherapy: moving beyond current vaccines
    Steven A Rosenberg
    Surgery Branch of the Center for Cancer Research at the National Cancer Institute, Building 10, Room 2B42, 10 Center Drive, MSC 1502 Bethesda, Maryland 20892 1502, USA
    Nat Med 10:909-15. 2004
    ..6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models...
  11. pmc The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors
    James W Hodge
    Recombinant Vaccine Group, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Semin Oncol 39:323-39. 2012
    Therapeutic cancer vaccines are a unique treatment modality in that they initiate a dynamic process of activating the host immune system, which can then be exploited by concurrent or subsequent therapies...
  12. ncbi HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells
    Toshiaki Yoshikawa
    Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Japan
    Cancer Sci 102:918-25. 2011
    ..These results suggest that GPC3(144-152) peptide vaccine can induce high avidity CTLs capable of killing HCC cells expressing GPC3. This trial was registered with University Hospital Medical Information Network number 000001395...
  13. ncbi Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia
    Gemma G Kenter
    Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands
    N Engl J Med 361:1838-47. 2009
    ..Spontaneous regression occurs in less than 1.5% of patients, and the rate of recurrence after treatment is high...
  14. pmc Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
    Philip W Kantoff
    Medical Director, BN ImmunoTherapeutics, 2425 Garcia Ave, Mountain View, CA 94043, USA
    J Clin Oncol 28:1099-105. 2010
    ..PROSTVAC-VF treatment was evaluated for safety and for prolongation of progression-free survival (PFS) and overall survival (OS) in a randomized, controlled, and blinded phase II study...
  15. pmc Improved endpoints for cancer immunotherapy trials
    Axel Hoos
    Cancer Immunotherapy Consortium of the Cancer Research Institute, New York, NY, USA
    J Natl Cancer Inst 102:1388-97. 2010
    ..These recommendations may improve our tools for cancer immunotherapy trials and may offer a more realistic and useful model for clinical investigation...
  16. ncbi Cancer immunotherapy by dendritic cells
    Cornelis J M Melief
    Department of Immunohematology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands ISA Pharmaceuticals, 3723 MB Bilthoven, The Netherlands
    Immunity 29:372-83. 2008
    ..Here, I discuss the considerations for generating promising therapeutic antitumor vaccines that use DCs...
  17. pmc Cancer regression in patients after transfer of genetically engineered lymphocytes
    Richard A Morgan
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Science 314:126-9. 2006
    ..This study suggests the therapeutic potential of genetically engineered cells for the biologic therapy of cancer...
  18. pmc Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses
    Marij J P Welters
    Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
    Proc Natl Acad Sci U S A 107:11895-9. 2010
    ..Foxp3(+) T cells have been associated previously with impaired immunity in malignancies. Here we demonstrate that the vaccine-prompted level of this population is associated with early treatment failure...
  19. doi Cancer immunology
    Olivera J Finn
    Department of Immunology, University of Pittsburgh School of Medicine, E1044, Biomedical Science Tower, Pittsburgh, PA 15261, USA
    N Engl J Med 358:2704-15. 2008
  20. pmc Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in
    Hideho Okada
    G12 a Research Pavilion at the Hillman Cancer Center, 5117 Centre Ave, Pittsburgh, PA 15213 1863, USA
    J Clin Oncol 29:330-6. 2011
    ..GAAs for these peptides are EphA2, interleukin (IL)-13 receptor-α2, YKL-40, and gp100...
  21. pmc 2011: the immune hallmarks of cancer
    Federica Cavallo
    Department of Clinical and Biological Sciences, University of Turin, Molecular Biotechnology Center, Via Nizza 52, 10126 Turin, Italy
    Cancer Immunol Immunother 60:319-26. 2011
    ....
  22. pmc Therapeutic cancer vaccines: current status and moving forward
    Jeffrey Schlom
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr, Rm 8B09, Bethesda, MD 20892, USA
    J Natl Cancer Inst 104:599-613. 2012
    ..The potential influence of the appropriate patient population and clinical trial endpoint in vaccine therapy studies is discussed, as well as the potential importance of biomarkers in future directions of this field...
  23. pmc CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
    Sergio A Quezada
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1935-45. 2006
    ....
  24. pmc Designing vaccines based on biology of human dendritic cell subsets
    Karolina Palucka
    Baylor Institute for Immunology Research, 3434 Live Oak Avenue, Dallas, TX 75204, USA
    Immunity 33:464-78. 2010
    ..In addition, we foresee that this increased knowledge will permit us to design vaccines that will reprogram the immune system to intervene therapeutically in cancer, allergy, and autoimmunity...
  25. pmc Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma
    Stephen J Schuster
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 29:2787-94. 2011
    ..To determine the clinical benefit of this vaccine, we conducted a double-blind multicenter controlled phase III trial...
  26. pmc Dendritic-cell-based therapeutic cancer vaccines
    Karolina Palucka
    Ralph M Steinman Center for Cancer Vaccines, Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, TX 75204, USA
    Immunity 39:38-48. 2013
    ..cell-based therapies such as adoptive transfer of ex-vivo-activated T cells and natural killer cells, and cancer vaccines. Herein, we discuss the immunological basis for therapeutic cancer vaccines and how the current understanding ..
  27. ncbi Cancer immunotherapy--revisited
    W Joost Lesterhuis
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre, P O Box 9101, 6500HB Nijmegen, The Netherlands
    Nat Rev Drug Discov 10:591-600. 2011
    ....
  28. ncbi Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine
    Paola Filipazzi
    Unit of Immunotherapy of Human Tumors and Unit of Medical Statistics and Biometry, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 25:2546-53. 2007
    ....
  29. pmc Monoclonal antibodies: versatile platforms for cancer immunotherapy
    Louis M Weiner
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Nat Rev Immunol 10:317-27. 2010
    ..These immunomodulatory properties can form the basis for new cancer treatment strategies...
  30. ncbi Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine
    Marij J P Welters
    Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
    Clin Cancer Res 14:178-87. 2008
    ..The study aims to evaluate the effect of a human papillomavirus type 16 (HPV16) E6 and E7 synthetic long peptides vaccine on the antigen-specific T-cell response in cervical cancer patients...
  31. pmc Prostate cancer as a model for tumour immunotherapy
    Charles G Drake
    Johns Hopkins Kimmel Cancer Center, 1650 Orleans Street CRB 410, Baltimore, Maryland 21231, USA
    Nat Rev Immunol 10:580-93. 2010
    ..Although this Review focuses on immunotherapy for prostate cancer, the principles discussed are applicable to many tumour types, and the approaches discussed are highlighted in that context...
  32. pmc Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy
    Robert M Prins
    Department of Neurosurgery, Brain Research Institute, the Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California 90095 6901, USA
    Clin Cancer Res 17:1603-15. 2011
    ..Clinical and immune responses were monitored and correlated with tumor gene expression profiles...
  33. ncbi Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity
    Anna K Palucka
    Baylor Institute for Immunology Research, Sammons Cancer Center, 3434 Live Oak, Dallas, TX 75204, USA
    J Immunother 29:545-57. 2006
    ..Thus, the present results justify the design of larger follow-up studies to assess the clinical response to DC vaccines loaded with killed allogeneic tumor cells in patients with metastatic melanoma...
  34. ncbi Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
    Matthew J Scanlan
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, Department of Pathology, New York, NY 10021, USA
    Immunol Rev 188:22-32. 2002
    ..Since CT antigens are immunogenic and highly restricted to tumors, their discovery has led directly to the development of antigen-specific cancer vaccines, and clinical trials with MAGE-A and NY-ESO-1 are in progress.
  35. pmc Clinical evaluation of TRICOM vector therapeutic cancer vaccines
    Ravi A Madan
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Semin Oncol 39:296-304. 2012
    ....
  36. ncbi Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
    Elisabeth Quoix
    Hopitaux Universitaires, Universite de Strasbourg, Strasbourg, France
    Lancet Oncol 12:1125-33. 2011
    ..This study assessed TG4010 in combination with first-line chemotherapy in advanced NSCLC...
  37. pmc Cancer vaccines and carbohydrate epitopes
    Jamie Heimburg-Molinaro
    Department of Biochemistry, Emory University, Atlanta, GA 30322, United States
    Vaccine 29:8802-26. 2011
    ..The role of each of the above mentioned carbohydrate antigens in cancer growth and metastasis and vaccine attempts using these antigens will be described...
  38. pmc Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans
    Duane A Mitchell
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA
    Blood 118:3003-12. 2011
    ....
  39. pmc 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines
    Rajesh K Sharma
    Department of Microbiology and Immunology, James Brown Cancer Center, Institute for Cellular Therapeutics, University of Louisville and ApoImmune, Inc, Louisville, Kentucky, USA
    Cancer Res 70:3945-54. 2010
    ....
  40. pmc Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients
    Qing Yi
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 150:554-64. 2010
    ..Current efforts are geared towards breaking tumour-mediated immune suppression and improving clinical efficacy of this immunotherapy...
  41. pmc NGcGM3 ganglioside: a privileged target for cancer vaccines
    Luis E Fernandez
    Vaccine Department, Center of Molecular Immunology, Havana, Cuba
    Clin Dev Immunol 2010:814397. 2010
    ..A brief discussion on the relevance of prioritization of cancer antigens in vaccine development is also included...
  42. pmc DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma
    Wim Maes
    Clinical Immunology, Department of Experimental Medicine, Leuven, Belgium
    Neuro Oncol 11:529-42. 2009
    ..They also show the beneficial effect of Treg depletion in this kind of glioma immunotherapy, even combined with DC vaccination...
  43. pmc Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response
    Anne M Ercolini
    Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Exp Med 201:1591-602. 2005
    ....
  44. pmc High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma
    Jochen Greiner
    Department of Internal Medicine III, University of Ulm, Albert Einstein Allee 23 89081 Ulm, Germany
    Haematologica 95:1191-7. 2010
    ..To improve the outcome of the vaccine, a second cohort was vaccinated with a higher dose of 1,000 microg peptide...
  45. pmc Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes
    Christopher M Long
    Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Res 69:3180-7. 2009
    ..This study shows the potential of magnetovaccination and MRI cell tracking to systematically evaluate a key parameter relevant to the optimization of vaccine therapies through noninvasive MRI-based quantification of APC numbers...
  46. ncbi Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
    Ravi A Madan
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet Oncol 13:501-8. 2012
    Therapeutic cancer vaccines have shown activity in metastatic castration-resistant prostate cancer (mCRPC), and methods are being assessed to enhance their efficacy...
  47. pmc The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance
    Bruce A Macher
    Department of Chemistry and Biochemistry, Science 246, 1600 Holloway Ave, San Francisco State University, San Francisco, CA 94132, USA
    Biochim Biophys Acta 1780:75-88. 2008
    ..This review covers these topics and new avenues of clinical importance related to this unique antigen/antibody system (alpha-gal epitope/anti-Gal) in improving the efficacy of viral vaccines and in immunotherapy against cancer...
  48. ncbi Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
    Alfons J M van den Eertwegh
    Department of Medical Oncology, VU University Medical Centre, Amsterdam, Netherlands
    Lancet Oncol 13:509-17. 2012
    ..We aimed to assess the safety of combined treatment with GVAX and ipilimumab in patients with metastatic castration-resistant prostate cancer (mCRPC)...
  49. ncbi In silico modeling and in vivo efficacy of cancer-preventive vaccinations
    Arianna Palladini
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Cancer Res 70:7755-63. 2010
    ..Finally, that the design and modeling of cancer vaccines and vaccination protocols must take into account the progressive aging of the immune system, by striving to ..
  50. ncbi Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer
    James L Gulley
    Laboratory of Tumor Immunology and Biology, Medical Oncology Clinical Research Unit, Radiation Oncology Branch, and Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:3353-62. 2005
    ..One potential solution is the utilization of a well-tolerated systemic therapy (e.g., vaccine) in concert with local therapy...
  51. ncbi Regulatory T cells in cancer
    Dimitrios Mougiakakos
    Department of Oncology and Pathology, Karolinska University Hospital, Cancer Center Karolinska R8 01, Stockholm, Sweden
    Adv Cancer Res 107:57-117. 2010
    ..Insight into the specific role of Tregs in different types of neoplasias is the key for targeting them in a way that is beneficial for the clinical outcome...
  52. pmc Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes
    Madhav D Sharma
    Department of Pediatrics, Medical College of Georgia, Augusta, GA 30912, USA
    Blood 113:6102-11. 2009
    ..Thus, Tregs in TDLNs can be actively reprogrammed in situ into T-helper cells, without the need for physical depletion, and IDO serves as a key regulator of this critical conversion...
  53. ncbi Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma
    John S Yu
    Maxine Dunitz Neurosurgical Institute, Cedars Sinai Medical Center, 8631 West Third Street, Suite 800E, Los Angeles, CA 90048, USA
    Cancer Res 64:4973-9. 2004
    ..We demonstrate for the first time the ability of an active immunotherapy strategy to generate antigen-specific cytotoxicity in brain tumor patients...
  54. ncbi Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors
    Theodora Fifis
    Austin Research Institute, Austin Hospital, Heidelberg, Victoria, Australia
    J Immunol 173:3148-54. 2004
    ..Thus, a range of Ags conjugated to nano-beads was effective as immunogens in both therapeutic and prophylactic scenarios...
  55. ncbi Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells
    Andrew J Rech
    Abramson Family Cancer Research Institute and the University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Ann N Y Acad Sci 1174:99-106. 2009
    ..If confirmed in additional patients, these observations suggest that daclizumab may be an effective and available therapeutic agent for Treg modulation in patients with cancer...
  56. ncbi Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme
    Steven De Vleeschouwer
    Department of Neurosurgery, Catholic University of Leuven, Leuven, Belgium
    Clin Cancer Res 14:3098-104. 2008
    ..To investigate the therapeutic role of adjuvant vaccination with autologous mature dendritic cells (DC) loaded with tumor lysates derived from autologous, resected glioblastoma multiforme (GBM) at time of relapse...
  57. pmc Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696
    John M Kirkwood
    Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 2584, USA
    Clin Cancer Res 15:1443-51. 2009
    ....
  58. pmc CD8+ T-cell memory in tumor immunology and immunotherapy
    Christopher A Klebanoff
    Howard Hughes Medical Institute National Institutes of Health NIH Research Scholars Program, Bethesda, MD 20892 1502, USA
    Immunol Rev 211:214-24. 2006
    ..Therapeutic vaccines for cancer and chronic infectious diseases may achieve consistent efficacy by ablation of the dysfunctional immune state and the provision of newly generated, non-corrupted memory cells by adoptive cell transfer...
  59. pmc Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
    Jens Dannull
    Genitourinary Cancer Immunotherapy Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Invest 115:3623-33. 2005
    ..Our findings may have implications in the design of immune-based strategies that may incorporate the Treg depletion strategy to achieve potent antitumor immunity with therapeutic impact...
  60. ncbi Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
    Eva Ellebaek
    Department of Haematology, Center for Cancer Immune Therapy, Copenhagen University Hospital, Herlev, Herlev Ringvej 75, 2730 Herlev, Denmark
    Cancer Immunol Immunother 61:1791-804. 2012
    ..A general increase in immune responses against the tested peptides was observed...
  61. ncbi Sipuleucel-T for the treatment of advanced prostate cancer
    Mark W Frohlich
    Dendreon Corp, Seattle, WA 98101, USA
    Semin Oncol 39:245-52. 2012
    ..The integration of sipuleucel-T into the treatment paradigm of advanced prostate cancer and future directions for research are discussed...
  62. pmc Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas
    Duane H Hamilton
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Semin Oncol 39:358-66. 2012
    ..We thus propose Brachyury as an attractive target for vaccination strategies designed to specifically target tumor cells undergoing EMT...
  63. ncbi Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides
    Paola Filipazzi
    Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Clin Cancer Res 18:6485-96. 2012
    ..dysfunctions that occur in patients with advanced melanoma make them unlikely to efficiently respond to cancer vaccines. A multicenter randomized phase II trial was conducted to test whether immunization with modified HLA class I ..
  64. ncbi Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients
    Pauline Verdijk
    Department of Tumor Immunology, Nijmegen Centre for Molecular Life Science, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Cancer Res 15:2531-40. 2009
    ..In this study, we investigated the fate of DC after intradermal (i.d.) or intranodal (i.n.) administration and the consequences for the immune activating potential of DC vaccines in melanoma patients...
  65. pmc Nanoparticle delivery systems in cancer vaccines
    Yogita Krishnamachari
    Department of Pharmaceutical Sciences and Experimental Therapeutics College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, USA
    Pharm Res 28:215-36. 2011
    ..Here, we review some recent advances in these colloidal and particulate nanoscale systems designed for cancer immunotherapy and the potential for these systems to translate into clinical cancer vaccines.
  66. ncbi Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years
    Mark H Einstein
    Montefiore Medical Center, Albert Einstein College of Medicine, Department of Obstetrics and Gynecology and Women s Health, Division of Gynecologic Oncology, Bronx, NY, USA
    Hum Vaccin 5:705-19. 2009
    ..Long-term studies evaluating duration of efficacy after vaccination are needed for both vaccines...
  67. pmc A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
    Tim F Greten
    Department of Gastroenterology, Hannover Medical School, Carl Neuberg Strasse 1, 30625 Hannover, Germany
    BMC Cancer 10:209. 2010
    ..In this open label, single arm clinical trial, we analyzed the effect of a low dose cyclophosphamide treatment in combination with a telomerase peptide (GV1001) vaccination in patients with advanced HCC...
  68. pmc Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses
    Elizabeth K Wansley
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:4316-25. 2008
    ..cerevisiae construct expressing human CEA (yeast-CEA) elicits CEA-specific T-cell responses and antitumor activity...
  69. pmc Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
    Peter Attia
    Surgery Branch, National Cancer Institute, National Institutes of Health, CRC, Room 3W 3940, 10 Center Dr, Bethesda, MD 20892 1201, USA
    J Clin Oncol 23:6043-53. 2005
    ..We have now treated 56 patients to evaluate two different dose schedules of anti-CTLA-4 and to explore the relationship between autoimmunity and tumor regression...
  70. pmc Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients
    Susanne M Rittig
    Department of Hematology, Oncology, Rheumatology and Immunology, Eberhard Karls University of Tuebingen, Tuebingen, Germany
    Mol Ther 19:990-9. 2011
    ..Induction of CD4(+) and CD8(+) T cell responses was shown for several tumor-associated antigens (TAA) using interferon-γ (IFN-γ) enzyme-linked immunosorbent spot (ELISpot) and Cr-release assays...
  71. ncbi Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study
    Hilko Ardon
    Department of Neurosurgery, University Hospital Leuven, Catholic University of Leuven, Herestraat 49, 3000 Leuven, Belgium
    J Neurooncol 99:261-72. 2010
    ..The survival data were used to power a currently running phase I/II trial...
  72. pmc Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors
    Rajesh K Sharma
    Institute for Cellular Therapeutics, Department of Microbiology and Immunology, and James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA
    Cancer Res 69:4319-26. 2009
    ..Potent pleiotropic immunomodulatory activities combined with lack of toxicity highlight the potential of 4-1BBL molecule as an effective component of therapeutic cancer vaccines.
  73. ncbi Multiple roles for CD4+ T cells in anti-tumor immune responses
    Richard Kennedy
    Mayo Vaccine Research Group, Mayo Clinic College of Medicine, Rochester, MN, USA
    Immunol Rev 222:129-44. 2008
    ..These unconventional roles for Th lymphocytes, which require direct cell-to-cell communication with CTLs, are clear examples of how versatile these immunoregulatory cells are...
  74. pmc Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes
    Eva Wieckowski
    Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Prostate 71:125-33. 2011
    ....
  75. ncbi Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
    Celestia S Higano
    Department of Oncology and Urology, University of Washington, Seattle, WA, USA
    Cancer 115:3670-9. 2009
    ..The safety and efficacy of sipuleucel-T was evaluated in 2 identically designed, randomized, double-blind, placebo-controlled trials (D9901 and D9902A) conducted in men with advanced prostate cancer...
  76. ncbi MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure
    R Dreicer
    Department of Solid Tumor Oncology Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA
    Invest New Drugs 27:379-86. 2009
    ..TG4010 is a recombinant MVA vector expressing the tumor-associated antigen MUC1 and IL2. We explored the effect two schedules of TG4010 on PSA in men with PSA progression...
  77. ncbi An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer
    P M Patel
    Academic Division of Clinical Oncology, University of Nottingham, Nottingham University Hospitals City Campus, Nottingham NG51PB, UK
    Eur J Cancer 44:216-23. 2008
    ..001). It is concluded that SRL172 may have activity in metastatic renal cancer and has very low toxicity, making it worthy of further study...
  78. ncbi Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation
    Maurizio Bendandi
    Laboratory of Immunology, Cell Therapy Area, University Clinic, Center for Applied Medical Research CIMA, School of Medicine, University of Navarre, Pamplona, Spain
    Leuk Lymphoma 47:29-37. 2006
    ..To combine the use of idiotype-pulsed allogeneic dendritic cells (alloDC) and soluble protein Id conjugated with KLH (Id-KLH) in a vaccine strategy for multiple myeloma (MM)...
  79. pmc Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
    Jacalyn Rosenblatt
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Blood 117:393-402. 2011
    ..Vaccination with DC/multiple myeloma fusions was feasible and well tolerated and resulted in antitumor immune responses and disease stabilization in a majority of patients...
  80. pmc Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity
    Biliang Hu
    Mork Family Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, CA 90089, USA
    Vaccine 28:6675-83. 2010
    ..Thus, this DC-directed IDLV system represents a promising and efficient vector platform with remarkably improved safety for the future development of DC-based immunotherapy...
  81. ncbi Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
    E J Small
    Department of Medicine and Urology, University of California San Francisco Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
    J Clin Oncol 18:3894-903. 2000
    ..Sequential phase I and phase II trials were performed to determine the safety and efficacy of Provenge and to assess its capacity to break immune tolerance to the normal tissue antigen PAP...
  82. ncbi Immunotherapy in multiple myeloma--possibility or probability?
    S J Harrison
    ATMU and Cancer Division, Section of Experimental Haematology, University of Glasgow, Glasgow, UK
    Br J Haematol 130:344-62. 2005
    ..We look at the clinical immunotherapy trials reported to date and whether, in light of the current information, immunotherapy for MM is an achievable goal...
  83. ncbi WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy
    Haruo Sugiyama
    Osaka University Graduate School of Medicine, Department of Functional Diagnostic Science, Osaka, Japan
    Jpn J Clin Oncol 40:377-87. 2010
    ..These findings suggest that a new era of WT1 immunotherapy is imminent...
  84. ncbi Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients
    Christopher J Wheeler
    Maxine Dunitz Neurosurgical Institute, Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, California, USA
    Cancer Res 68:5955-64. 2008
    ..clinical improvements as observed in animal models, fueling controversy over the utility of human cancer vaccines. Therapeutic vaccination represents an intriguing additional therapy for glioblastoma multiforme (GBM; grade ..
  85. ncbi NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, New York Branch, Memorial Sloan Kettering Cancer Center, New York, USA
    Clin Cancer Res 15:2130-9. 2009
    ..Here, we report for the first time clinical and immune responses generated by the NY-ESO-1 DNA vaccine administered by particle-mediated epidermal delivery to cancer patients...
  86. ncbi A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
    Ulrich Keilholz
    Department of Hematology and Oncology, Charite Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, Germany
    Blood 113:6541-8. 2009
    ..18% at baseline and 0.41% in week 18. This WT1 vaccination study provides immunologic, molecular, and preliminary evidence of potential clinical efficacy in AML patients, warranting further investigations...
  87. ncbi Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer
    Elia Neninger Vinageras
    Hospital Hermanos Ameijeiras, San Lazaro 701, PO Box 10300, Ciudad Habana, Cuba
    J Clin Oncol 26:1452-8. 2008
    ..We show the result of a randomized phase II clinical trial with an epidermal growth factor (EGF)-based cancer vaccine in advanced non-small-cell lung cancer (NSCLC) patients, evaluating immunogenicity, safety, and effect on survival...
  88. ncbi Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer
    Frank M Speetjens
    Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
    Clin Cancer Res 15:1086-95. 2009
    ..The safety and immunogenicity of a p53 synthetic long peptide (p53-SLP) vaccine were investigated in patients treated for metastatic colorectal cancer...
  89. pmc Recent developments in cancer vaccines
    Karolina Palucka
    Baylor Institute for Immunology Research, Baylor University Medical Center, Dallas, TX 75204, USA
    J Immunol 186:1325-31. 2011
    ..Recent successful phase III clinical trials showing benefit to the patients revived cancer vaccines. Dendritic cells (DCs) are essential in generation of immune responses, and as such represent targets and ..
  90. pmc Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines
    Michael A Morse
    Department ofMedicine, Duke University Medical Center, Durham, NC 27710, USA
    Blood 112:610-8. 2008
    ....
  91. pmc Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
    F Stephen Hodi
    Department of Adult Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:4712-7. 2003
    ..that block CTLA-4 function inhibits the growth of moderately immunogenic tumors and, in combination with cancer vaccines, increases the rejection of poorly immunogenic tumors, albeit with a loss of tolerance to normal ..
  92. pmc Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas
    Claudia Curcio
    Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy
    J Clin Invest 111:1161-70. 2003
    ..Moreover, vaccination cured half of the CD1 and the majority of the MCP1 KO mice. The eradication of established p185(neu) carcinomas involves distinct mechanisms, each endowed with a different curative potential...
  93. ncbi Vaccines for tumour prevention
    Pier Luigi Lollini
    Section of Cancer Research, Department of Experimental Pathology, University of Bologna, Italy
    Nat Rev Cancer 6:204-16. 2006
    ....
  94. ncbi Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial
    Elia Neninger
    Hermanos Amejeiras Hospital, Havana City, Cuba 10300
    Cancer Biol Ther 6:145-50. 2007
    ..A prolonged survival was observed in several patients treated with the anti-idiotype vaccine. No evidence of serious adverse effects was found...
  95. ncbi Dendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma protein
    A W Butch
    Department of Pathology and Laboratory Medicine, UCLA Medical Center, 10833 Le Conte Ave, Mailroom A2 179 CHS, Los Angeles, CA 90095 1732, USA
    Exp Hematol 29:85-92. 2001
    ..This demonstrates the feasibility of using all classes of myeloma protein for producing DC vaccines, and defines culture conditions for optimizing antigen loading of DCs for induction of anti-myeloma responses...
  96. ncbi Immunological aspects of cancer chemotherapy
    Laurence Zitvogel
    INSERM, U805, Institut Gustave Roussy, 39 rue Camille Desmoulins, F 94805 Villejuif, Paris, France
    Nat Rev Immunol 8:59-73. 2008
    ..Here, we review the immunological aspects of conventional cancer treatments and propose that future successes in the fight against cancer will rely on the development and clinical application of combined chemo- and immunotherapies...
  97. ncbi Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells
    Volker L Reichardt
    Department of Hematology, Oncology, Immunology and Rheumatology, University of Tubingen, Tubingen, Germany
    Haematologica 88:1139-49. 2003
    ..Dendritic cells (DC) pulsed with multiple myeloma (MM) patient-specific idiotype (Id) protein can induce MM-specific T-cell responses...
  98. pmc Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming
    Danila Valmori
    Ludwig Institute Clinical Trial Center, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 104:8947-52. 2007
    The use of recombinant tumor antigen proteins is a realistic approach for the development of generic cancer vaccines, but the potential of this type of vaccines to induce specific CD8(+) T cell responses, through in vivo cross-priming, ..
  99. ncbi HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice
    R T Reilly
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Cancer Res 60:3569-76. 2000
    ..These transgenic mice provide a spontaneous tumor model for identifying vaccine approaches potent enough to overcome mechanisms of immune tolerance that are likely to exist in patients with cancer...
  100. ncbi Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer
    Motoki Miyazawa
    Second Department of Surgery, Wakayama Medical University, Wakayama, Japan
    Cancer Sci 101:433-9. 2010
    ..From an immunological point of view, the optimal dose for further clinical trials might be 2 mg/body or higher. This trial was registered with ClinicalTrial.gov (no. NCT 00622622)...
  101. ncbi Tumor antigen-specific T helper cells in cancer immunity and immunotherapy
    K L Knutson
    Department of Immunology, Mayo Clinic College of Medicine, 342C Guggenheim Bldg, 200 First St SW, Rochester, MN 55906, USA
    Cancer Immunol Immunother 54:721-8. 2005
    ....

Research Grants79

  1. Metabolic Engineering of Bacteria for Cancer Immunotherapy by Gamma Delta T Cells
    Craig T Morita; Fiscal Year: 2013
    ..Both species have been used for cancer vaccines but differ significantly since the Gram negative Salmonella uses the MEP pathway and is given orally whereas ..
  2. Gold Nanoparticle Assisted Delivery of Cancer Vaccines and Immune Stimulants
    Adam Lin; Fiscal Year: 2013
    ..b>Cancer vaccines utilize the immune system to generate a sustainable and specific anti-tumor response, providing a promising ..
  3. Proteome Bead-Display for Discovery of Tumor Antigens
    Mark Lim; Fiscal Year: 2013
    ..In addition to use in early diagnosis, such TAAs have great value in developing anti-cancer vaccines and potentially guiding individualized patient therapy...
  4. Vaccines to promote Tc-1-based targeting of tumor stroma
    Walter J Storkus; Fiscal Year: 2013
    ..These results may provide the translational inertia to develop vaccine and combinational therapies targeting the tumor stroma that can be applied to patients harboring any type of vascularized cancer. ..
  5. HA Surface Presented Yeast Flu Vaccine and Its Enhancement by CD154 Codisplay
    Kaiming Ye; Fiscal Year: 2012
    ..be used for massive and rapid manufacturing not only avian influenza vaccines but also other vaccines such as cancer vaccines. Thus, this technology has the potential to impact broadly on our ability to treat and prevent virus-related ..
  6. Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)
    Javier Pinilla; Fiscal Year: 2012
    ..Importantly, animal models of IMiDs combined with cancer vaccines suggest that these drugs selectively enhance anti-tumor specific T-cell responses...
  7. Development of Breast Cancer Vaccines
    WEI ZEN NONE WEI; Fiscal Year: 2013
    ..Novel DNA constructs that combine heterologous and self antigen sequences will be tested as therapeutic cancer vaccines. To amplify vaccine activity, the effect of reducing natural and inducible regulatory T cells and ..
  8. Enterovirus Vectors with Respiratory Tropism for Cancer Immunotherapy
    Matthias Gromeier; Fiscal Year: 2010
    ..Efficacious cancer vaccines may require combined responses directed against the tumor itself and mechanisms of immune tolerance...
  9. GUCY2C targeted adoptive T cell therapy to treat metastatic colorectal cancer
    Michael S Magee; Fiscal Year: 2013
    ..In that context, cancer vaccines that mobilize immune responses to tumor antigens in patients fail to eradicate established metastases, ..
  10. MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES
    CRAIG LEE SLINGLUFF; Fiscal Year: 2012
    ..PUBLIC HEALTH RELEVANCE: Cancer vaccines hold promise as a low toxicity treatment that may harness the immune system's response to cancer, and to ..
  11. Durable CD4+ T-cell Tumor Immunity Following Gene-modified HPSC
    Christopher E Touloukian; Fiscal Year: 2013
    ..have included potent cytokine infusions, the adoptive transfer of activated lymphocytes, and a wide array of cancer vaccines, have been largely applied to patients with metastatic melanoma...
  12. Immunotherapeutic HPV cancer vaccines that target Langerhans cells
    Gerard Zurawski; Fiscal Year: 2010
    ..The results of this study will also have immediate implications for the rational design and development of vaccines against other cancers and infections. Importantly, this work will allow preservation and creation of jobs. ..
  13. Vaccination with IL-15 DC to Generate Melanoma-specific Protective Memory T Cells
    Anna Karolina Palucka; Fiscal Year: 2013
    ..This concept is fundamental for the development of effective cancer vaccines. We found that IL15- DCs are more efficient than IL4-DCs in priming and maturation of melanoma antigen-..
  14. Novel Strategies for Cancer Immunotherapy in Stem Cell Transplant
    Yiping Yang; Fiscal Year: 2013
    ..Therefore, the key is to develop cancer vaccines capable of overcoming regulatory T cell-mediated suppression and effectively activate anti-tumor immunity...
  15. Using the MHC class I cytoplasmic tail to control tumor Ag presentation by DCs
    Gregory A Lizee; Fiscal Year: 2013
    ..the ability to improve tumor antigen loading and extend duration of antigen presentation in human DC-based cancer vaccines, thus improving CTL priming outcomes...
  16. Metabolic Engineering of Cancer for Immunotargeting
    Zhongwu Guo; Fiscal Year: 2012
    ..cures for cancer by immunotherapy, namely to treat patients with anticancer antibodies or with therapeutic cancer vaccines that can provoke anticancer immunities, which is considered the ideal therapy for cancer due to its ..
  17. Predictors of clinical outcome after therapeutic vaccination in follicular lympho
    Sattva S Neelapu; Fiscal Year: 2013
    ..anti-tumor immune effectors (antibodies and T-cells) is a necessary condition for clinical efficacy of cancer vaccines;however, the efficacy of these effectors, and perhaps even their generation by vaccination, may be opposed by ..
  18. CD4+ Memory T-Cells in Human Tumor Microenvironment
    Richard B Bankert; Fiscal Year: 2013
    ..basis for the design of new strategies that could be used to enhance the therapeutic effectiveness of current cancer vaccines. PUBLIC HEALTH RELEVANCE: Cancer vaccines induce tumor-specific T cells that circulate in the peripheral ..
  19. A New Anti-CD27 Monoclonal Antibody Adjuvant for Pancreatic Cancer Vaccines
    SARAH JANE SCHLESINGER; Fiscal Year: 2013
    ..that agonistic anti-CD27 antibody will be a superior adjuvant to improve the efficacy of pancreatic cancer vaccines, by ensuring delivery of the CD70 signal. This can be approached with new available tools...
  20. Immunotherapy for Chronic Myelogenous Leukemia
    Emmanuel Katsanis; Fiscal Year: 2013
    ..is a competing renewal designed to pursue our studies on the development of novel therapies, specifically cancer vaccines, for chronic myelogenous leukemia (CML)...
  21. MELANOMA VACCINE FOR HELPER T CELLS COMBINED WITH TARGETED OR IMMUNE THERAPIES
    CRAIG LEE SLINGLUFF; Fiscal Year: 2013
    ..b>Cancer vaccines inducing antigen-specific T cell responses are emerging as a component of combination immunotherapy...
  22. Overcoming Inferior Quality of Vaccine Responses After Alkylating Chemotherapy
    Adam J Litterman; Fiscal Year: 2013
    ..1 While anecdotal reports of individual patient benefit after receiving cancer vaccines for malignant glioma are promising,2-5 the overall record of vaccines for the treatment of this disease has ..
  23. Development of an in vivo screening technology for cancer vaccine immunogens
    Steven L Zeichner; Fiscal Year: 2013
    ..to develop a highly novel and previously untested technology to identify, assess, and compare immunogens for cancer vaccines, employing an in vivo immune system in a high throughput screening mode...
  24. Activating robust immunity to tumor-associated antigens:mechanisms and biology
    Edith M Janssen; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Therapeutic cancer vaccines are intended to drive specific activation of the immune system for therapy of existing malignancies or prevention of their recurrence...
  25. Expressing New Tumor Antigens by Inhibition of Nonsense Mediated mRNA Decay
    Eli Gilboa; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: Cancer vaccines aims at eliciting a potent antitumor immune responses capable of seeking out and destroying the disseminated ..
  26. Novel Approaches for Structural Determination of Cancer Stem Cell Glycans
    Kristina Hakansson; Fiscal Year: 2012
    ..glycan structures, which are required for generation of novel diagnostics and therapeutics, including cancer vaccines, are scarce. Mass spectrometry (MS) can provide sensitive and accurate glycan analysis...
  27. rAAV vaccine vector
    Selvarangan Ponnazhagan; Fiscal Year: 2012
    ..Unique advantages of recombinant adeno-associated virus vector (rAAV) in the development of effective cancer vaccines include induction of sustained, high-level transgene expression, absence of viral structural proteins, non-..
  28. Reversal of regulatory T cell function in prostate cancer
    Rongfu Wang; Fiscal Year: 2010
    ..may explain, at least in part, why attempts to elicit strong and durable antitumor responses with cancer vaccines (comprising MHC class l-restricted tumor antigens or peptides) have been largely unsuccessful...
  29. Molecular Pharmacology of NKT Cell Agonists
    Luc Teyton; Fiscal Year: 2013
    ..critical to vaccine development, immunotherapy of chronic infectious diseases, prevention of infection, and cancer vaccines. However, success will rely heavily on our ability to translate the knowledge of mouse NKT biology to humans...
  30. Chitosan-based Delivery and Immunopotentiation of Cancer Vaccines
    David Zaharoff; Fiscal Year: 2012
    ..This project will study the mechanisms by which chitosan enhances the antitumor activity of IL-12 and support the potential clinical translation of chitosan/IL- 12 immunotherapy. ..
  31. Cancer Immunotherapy by Targeting A2 Adenosine Receptor
    Michail Sitkovsky; Fiscal Year: 2013
    ..2, 3, we will establish the upper limit of anti-A2AR-adenosinergic anti-tumor treatment in combination with cancer vaccines and CTLA-4 antibody blockade and clarify the molecular and immunological consequences of targeting A2AR on ..
  32. Vaccine-Dac/Bev Combinatorial Therapy in Ovarian Cancer
    George Coukos; Fiscal Year: 2012
    ..However, cancer vaccines have produced modest results to date...
  33. Tolerance mechanisms regulating the complete HER-2/neu CD+8 T cell repertoire
    Elizabeth M Jaffee; Fiscal Year: 2012
    ..induction are that cancer-specific high avidity T cell populations are deleted or suppressed, and that cancer vaccines must either break tolerance in anergic T cells or activate populations of low avidity T cells which, based on ..
  34. Designing Lymph Nodes for Cancer Immunotherapy
    JAMES J MULE; Fiscal Year: 2013
    ..b>Cancer vaccines are a significant part of the immunotherapy armamentarium...
  35. TCR Engineered CD4 Cells as Helpers in Tumor Immunity
    Bijay Mukherji; Fiscal Year: 2012
    ..PUBLIC HEALTH RELEVANCE: "Cancer vaccines" and adoptive cell therapy for cancer have shown promising results but the two basic approaches need new ..
  36. Using FAP to Selectively Target Epithelial Cancers
    William W Bachovchin; Fiscal Year: 2013
    ..Understanding of the possible immunoregulatory functions of FAP is particularly important. Cancer vaccines can prime T cells against tumor antigens;but the immune responses seldom produce durable tumor regression ..
  37. Promoting the generation of long-lived, anti-tumor memory T cells with IFN-alpha
    Willem W Overwijk; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Cancer vaccines and adoptive T cell transfer approaches hold promise for cancer treatment and the prevention of tumor recurrence...
  38. A membrane-based immunotherapy for triple negative breast cancer
    Christopher D Pack; Fiscal Year: 2013
    ..different from previous studies that used gene transfer techniques or secretory cytokines to develop cancer vaccines. The major advantage is that the immunotherapy preparation can be accomplished within just a few days...
  39. Modulating AhR in tumor and lymphoid microenvironments via local drug delivery
    GREGORY SZETO; Fiscal Year: 2013
    ..g., chemotherapy, radiation) and novel immunotherapies (e.g., adoptive cell transfer, cancer vaccines) remains the persistent state of immunosuppression induced and sustained by cancers...
  40. Antigen specificity, suppressive mechanism & regulation of CD4+ regulatory T cell
    Rongfu Wang; Fiscal Year: 2010
    ..may explain, at least in part, why attempts to elicit strong and durable antitumor responses with cancer vaccines (comprising MHC class I- restricted tumor antigens or peptides) have been largely unsuccessful...
  41. Multidisciplinary approaches to tumor immunology
    Kelvin P Lee; Fiscal Year: 2013
    ..in understanding the significant role of endogenous anti-tumor immunity in cancer patients, preventive anti-cancer vaccines (e.g. the anti-HPV vaccine Gardasil(r)), and clinically effective immunotherapy (e.g...
  42. Tumor antigen-decorated virus-like particles as a therapeutic cancer vaccine
    Jaina Patel; Fiscal Year: 2013
    ..The knowledge obtained from these studies will form a foundation to develop VLP-based efficacious therapeutic cancer vaccines to treat existing tumors or lead to the prevention of metastatic growth in humans.
  43. Helper and suppressor roles of CD8+ T cells
    Julie Urban; Fiscal Year: 2009
    ..the addition of a tumor-irrelevant (LCMV-gp33) peptide to tumor-lysate loaded DC can increase the efficacy of cancer vaccines administered in therapeutic settings in the presence of pre-existing tumor-specific immunity...
  44. Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
    Donald W Kufe; Fiscal Year: 2013
    ..agents, angiogenesis inhibitors, signal transduction/cell cycle inhibitors, differentiating agents and anti-cancer vaccines. Trials performed over the past 4 years (2003-2006, prior funding period) include 10 agents from the NCI ..
  45. The Use of Novel Implantable Cancer Vaccines for the Treatment of Oral Cancer
    Simon Young; Fiscal Year: 2013
    ....
  46. Role of Retromer-mediated Retrograde Transport in HPV Entry
    DANIEL C DIMAIO; Fiscal Year: 2013
    ..Overall, these experiments will elucidate the mechanistic details of HPV entry, provide new insights into fundamental cell biology, and suggest novel anti-viral strategies. ..
  47. Continuous separation of melanoma exosomes using field-flow fractionation
    Samuel A Wickline; Fiscal Year: 2013
    ..Consequently, exosomes are showing promise as cancer vaccines and have even been modified to deliver siRNA across the blood brain barrier...
  48. Docking DRibbles to dendritic cells via C-type lectin receptors
    Hong Ming Hu; Fiscal Year: 2010
    ..been done), but potentially highly rewarding (huge improvement in vaccine design and large impact on DC based cancer vaccines)...
  49. Arginine Availability, Modulated by MDSC, Regulates T Cell Function in Cancer
    Augusto C Ochoa; Fiscal Year: 2013
    ..b>Cancer vaccines and cytokines can be an important therapeutic approach for patients whose tumors have failed standard forms ..
  50. GENERATING CTL AGAINST TUMOR ASSOCIATED PEPTIDE ANTIGENS
    Linda A Sherman; Fiscal Year: 2012
    ..The goal of this project is to improve cancer vaccines and immunotherapy so that they may be used as a reliable method for treatment of cancer patients.
  51. Pou6f1 transcriptional control of memory CD8+ T cells
    CHANCE MARION JOHN LUCKEY; Fiscal Year: 2012
    ..circuitry of CD8+ T cell memory, its targets, and the upstream signaling network that drives it will provide potential therapeutic candidates that might be used to aid in the design of more efficacious therapeutic cancer vaccines.
  52. Mechanisms That Regulate Tumor-Specific Immune Responses
    Bernard A Fox; Fiscal Year: 2013
    ..Recent work from our group has identified that multiple administrations of cancer vaccines, instead of boosting the immune response, turns the immune system off...
  53. The Role of CD4+ T Cells in Antitumor Immunity
    Rongfu Wang; Fiscal Year: 2013
    ..In order to develop effective cancer vaccines, it is necessary to have a better understanding of the generation and suppressive mechanisms of CD4+ ..
  54. Institute of Human Virology Annual Meeting 2011-2016
    Robert C Gallo; Fiscal Year: 2013
    ..We held discussions of cancer-causing viruses and new cancer vaccines. Cancer is emerging as the leading cause of death for persons with HIV;these fields are linked in terms of ..
  55. Nanostructured Cancer Vaccines
    T Andrew Taton; Fiscal Year: 2010
    ..Assay binding specificity of functionalized naAPCs to T cells, and compare avidity to that of microsphere- based aAPCs;and 4. Assay T-cell activation and differentiation in vitro, and compare to aAPCs. ..
  56. Biomaterial based breast cancer vaccine
    David J Mooney; Fiscal Year: 2013
    ..Currently, many experimental cancer vaccines isolate and program immune cells outside the body, and introduce the programmed cells back into the patient (..
  57. Virus-Like Particle Based Antigen Display as Multi-component Anticancer Vaccines
    Xuefei Huang; Fiscal Year: 2013
    ..immune responses but also provide valuable pre- clinical information for future clinical evaluation of anti-cancer vaccines. PUBLIC HEALTH RELEVANCE: Cancer is a major cause of mortality in the world...
  58. B7-H1/PD-1 modulation in cancer therapy
    SUZANNE LOUISE TOPALIAN; Fiscal Year: 2013
    ..antitumor immune responses - including endogenous responses and those induced by immunotherapies such as cancer vaccines. Animal cancer models demonstrate that blocking the interaction of inhibitory molecules on tumor cells with ..
  59. Novel Strategies for Immunotherapy of Cancer
    Rongfu Wang; Fiscal Year: 2013
    ..of both MHC class I and II restricted antigens has provided opportunities to develop more effective cancer vaccines, however, current immunotherapy strategies with tumor antigens are relatively ineffective and have not ..
  60. Induction of cytotoxic T cells by pulmonary dendritic cells
    Claudia V Jakubzick; Fiscal Year: 2013
    ..While this approach is highly promising, we believe that the development of DC-based cancer vaccines will be substantially enhanced by exploiting the different functional roles played by specific DC subtypes ..
  61. Comprehensive SDSU/UCSD Cancer Center Partnership 1 of 2
    Stanley R Maloy; Fiscal Year: 2013
    Significant advances in biotechnology and biochemistry have led to the discovery of a large number of cancer vaccines based on peptides and proteins...
  62. ApoVax104-HPV as a Novel Vaccine for Cervical Cancer
    KATHRYN MACLEOD; Fiscal Year: 2009
    ..Regardless of significant advances in vaccinology, the therapeutic potential of cancer vaccines remains to be realized, partly due to an array of evasive and immunosuppressive mechanisms employed by ..
  63. Pilot trial of a DNA vaccine encoding PAP in patients with prostate cancer
    Douglas McNeel; Fiscal Year: 2009
    ..Our laboratory has been seeking to define appropriate antigens for inclusion in prostate cancer vaccines, target these antigens in rodent models using plasmid DNA vaccines, and ultimately to translate these ..
  64. Psychological stress, cortisol, and B lymphocyte decrements
    Bonnie McGregor; Fiscal Year: 2007
    unreadable] DESCRIPTION (provided by applicant): Cancer vaccines are emerging as important tools for cancer treatment and prevention...
  65. Targeted EGFR Antisense Gene Therapy of Brain Cancer
    RUBEN BOADO; Fiscal Year: 2005
    ..None of the large molecule drugs (monoclonal antibodies, cancer vaccines, gene therapies) cross the BBB, and >98% of small molecule cancer therapeutics do not cross the BBB...
  66. TECHNOLOGY FOR CULTURE OF MEGATHURA CRENULATA FOR KLH
    DAVID SPAULDING; Fiscal Year: 2007
    ..grade, quality-controlled Keyhole Limpet Hemocyanin (KLH) products ready for use in an expanding array of cancer vaccines, immunological uses and other biomedical applications s_jnported by the NIH and pdvate industry. With...
  67. Multi-Antigen Vaccines for Breast Cancer
    MARY DISIS; Fiscal Year: 2007
    ..For this reason, cancer vaccines have theoretical appeal as a chemopreventive agent in breast cancer...
  68. Trojan Antigens: A Multiple-Epitope Vaccine for Cancer
    Esteban Celis; Fiscal Year: 2007
    ..We believe that by completing the above specific aims, we will generate sufficient preclinical data to take this approach into the clinic. ..
  69. CANCER VACCINES TO HPV-16 ASSOCIATED TUMOR
    Hildegund Ertl; Fiscal Year: 2001
    ..In case the applicant's hypothesis is correct, data gathered within the realm of this application will serve as the basis for a clinical Phase I trial. ..
  70. Chemokine Potential in Cancer Immunotherapy
    Dean Johnston; Fiscal Year: 2002
    ..b>Cancer vaccines offer superior theoretical therapy because they can induce long-term immunity directed specifically against ..
  71. Phase 1b Active Immunotherapy with HER-2 Multi-epitope v
    Pravin Kaumaya; Fiscal Year: 2003
    ..However, the optimal design, formulation and composition of future cancer vaccines have yet to be determined and clinical responses, especially in conjunction with vaccine immune responses, ..
  72. Melanoma Vaccines with Peptides, Protein and Adjuvant
    Hassane Zarour; Fiscal Year: 2009
    ..We now propose to perform clinical trials to assess the in vivo efficacy of cancer vaccines with T-helper epitopes in patients with melanoma...
  73. Chitosan-plasmid DNA nanoplexes and adenoviruses as prostate cancer vaccines
    ALIASGER SALEM; Fiscal Year: 2009
    ....
  74. Nanoliter Lab-on-a-Chip for Rapid Parallel Immunoassays
    Vamsee Pamula; Fiscal Year: 2006
    unreadable] DESCRIPTION (provided by applicant): The development of clinically effective cancer vaccines requires reliable analytical methods to evaluate the immune response to vaccination...
  75. Tumor cell antigen presentation to CD4 + T lymphocytes
    Suzanne Ostrand Rosenberg; Fiscal Year: 2004
    DESCRIPTION: (Adapted from applicant's abstract) Our long-term goal is to generate cell-based cancer vaccines for the treatment of established metastatic cancer, particularly metastatic breast cancer...
  76. Mucosal RSV vaccine using CpG oligodeoxynucleotides
    Gregory Prince; Fiscal Year: 2003
    ..Phase II activities would use that information to formulate a vaccine that would be both effective and safe. ..
  77. Listeria PEST Sequence Fusion Proteins as Tumor Vaccines
    SHAHABI VAFA; Fiscal Year: 2004
    ..We have been actively involved in optimizing the delivery and antigenicity of tumor associated antigens for cancer vaccines for future development of human therapeutics. Paterson et al...
  78. CD8+ T cell Activation and Infiltration Into Breast Tumors Following Vaccination
    KIMBERLY A contact BULLOCK; Fiscal Year: 2010
    ..The proposed will address two fundamental questions related to peptide-based breast cancer vaccines. First, are vaccine-induced T cells trafficking to and penetrating into tumor and second, are the activated T ..
  79. New Cancer Vaccine Technology Based on DRibbles Produced by Tumor Cells
    Sandra Aung; Fiscal Year: 2006
    unreadable] DESCRIPTION (provided by applicant): A major hurdle for the development of effective cancer vaccines is the inability of most currently available cancer vaccines to induce a robust immune responses against a broad spectrum ..